BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo
TheFly reported on February 18 that Wells Fargo & Company increased its price target for BMRN from $70 to $75 while keeping an Overweight rating.







